The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC).
 
Omar Alhalabi
No Relationships to Disclose
 
Nathaniel Wilson
No Relationships to Disclose
 
Lianchun Xiao
No Relationships to Disclose
 
Neema Navai
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Eisai; EnGeneIC; FerGene; Imagin Medical; Janssen; Medac; Merck; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FerGene; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Photocure; Seagen; SWOG; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
John C. Araujo
No Relationships to Disclose
 
Jianbo Wang
No Relationships to Disclose
 
Sangeeta Goswami
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Janssen Biotech; Jounce Therapeutics; Pfizer; Seagen; Symphogen
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Jennifer Wang
No Relationships to Disclose
 
Charles Guo
No Relationships to Disclose
 
Bogdan Czerniak
No Relationships to Disclose
 
Paul Gettys Corn
Research Funding - Janssen Oncology (Inst)
 
Christopher Logothetis
Honoraria - Amgen; Bayer; Merck Sharp & Dohme
Consulting or Advisory Role - Amgen; Bayer; Exelixis; Merck Sharp & Dohme
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis; ORIC Pharmaceuticals (Inst)
 
Colin P.N. Dinney
Consulting or Advisory Role - FKD Therapies; NCI; The University of Eastern Finland, Faculty of Health Sciences (UEFHS)
Research Funding - FKD Therapies; Merck; NCI; University of Eastern Finland (Inst)
 
Matthew T Campbell
Honoraria - Apricity Health; Apricity Health (Inst); Aravive (Inst); Astellas Pharma; AstraZeneca (Inst); Axdev; Eisai; EMD Serono; Exelixis; Exelixis (Inst); Genentech/Roche; Janssen Oncology (Inst); Medscape; Pfizer; Pfizer (Inst); Seagen
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Exelixis; Genentech; Pfizer
Research Funding - Apricity Health (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Pfizer; Roche
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Ipsen; Lilly; Nektar; Pfizer; Surface Oncology
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.